- Category
- Micro (2023-24)
- Udyam number
- UDYAM-UP-56-0035076

About Mediflorence Medicaments Limited
Data last updated:
Mediflorence Medicaments Limited is a public limited company based in New Delhi, Delhi, India. It operates in the pharmaceutical retail and distribution segment of the pharmaceuticals sector. It was incorporated on 09 February 2012 and has been in existence for over 14 years.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U24100DL2012PLC231292. Its GSTIN is 09AAICM4762C1ZF (Uttar Pradesh).
The company has an authorised share capital of ₹10 Lakh and a paid-up capital of ₹10 Lakh. It is led by directors including Sunil Kumar Sharma and Vibhu Sharma.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at B – 86 R Block Dilshad Garden, New Delhi, Delhi, India – 110095.
As per the financials filed for FY 2025, the company reported a revenue of ₹5.62 Cr, a growth of 6% compared to the previous year. For the same year it recorded a net profit of ₹3.25 Lakh (net margin 0.6%) and EBITDA of ₹10.98 Lakh (EBITDA margin 2%). Revenue has grown at a compounded annual rate (CAGR) of 11% over three years and 13% over five years.
The company is associated with 1 brand: Mediflorence. As per MCA filings, the company has open charges of ₹20 Lakh on record.
Mediflorence Medicaments Limited is registered as a micro enterprise under the Udyam registration framework (Reg. No. UDYAM-UP-56-0035076). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website mediflorence.com.
Recognitions & Rankings of Mediflorence Medicaments
- EmailLocked
- TelephoneLocked
- Website
- Social MediaLocked
- Registered AddressB – 86 R Block Dilshad Garden, New Delhi, Delhi, India – 110095
- IndustryPharma, Pharmaceutical Retailers & Distributors
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Associated Brands
Mediflorence Medicaments operates one associated brand: Mediflorence. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Pharmaceutical manufacturing, marketing, and distribution of medicines in India. | mediflorence.com |
Business Activity
The main business activity of Mediflorence Medicaments is trade. In detail, this covers wholesale trading.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Financials of Mediflorence Medicaments Limited
FY 2025 filings availableMediflorence Medicaments Limited reported revenue of ₹5.62 Cr (up 6% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 13% over five years, including 6% growth in the latest year. EBITDA fell 7% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2020-21 to FY 2023-24in the company report |
|---|---|---|
| Profit and Loss Statement | ||
| Revenue from Operations | •••• | |
| Other Income | •••• | |
| Total Revenue | •••• | |
| Cost of Materials Consumed | •••• | |
| Employee Benefit Expense | •••• | |
| Finance Costs | •••• | |
| Depreciation and Amortisation | •••• | |
| Other Expenses | •••• | |
| Total Expenses | •••• | |
| EBITDA | ₹10.98 Lakh | |
| Profit Before Tax | •••• | |
| Tax Expense | •••• | |
| Net Profit (PAT) | ₹3.25 Lakh | |
| Balance Sheet | ||
| Share Capital | •••• | |
| Reserves and Surplus | •••• | |
| Net Worth (Total Equity) | •••• | |
| Long-term Borrowings | •••• | |
| Short-term Borrowings | •••• | |
| Trade Payables | •••• | |
| Total Liabilities | •••• | |
| Fixed Assets | •••• | |
| Investments | •••• | |
| Inventories | •••• | |
| Trade Receivables | •••• | |
| Cash and Bank Balance | •••• | |
| Total Assets | •••• | |
Financial Ratios
| Metrics | FY 2024-25 | FY 2020-21 to FY 2023-24in the company report |
|---|---|---|
| Profitability | ||
| EBITDA Margin | 2% | |
| Net Profit Margin | 0.6% | |
| Return on Equity (ROE) | •••• | |
| Return on Capital Employed (ROCE) | •••• | |
| Return on Assets (ROA) | •••• | |
| Liquidity and Debt | ||
| Current Ratio | •••• | |
| Quick Ratio | •••• | |
| Debt-to-Equity Ratio | •••• | |
| Interest Coverage Ratio | •••• | |
| Efficiency and Growth | ||
| Asset Turnover | •••• | |
| Receivable Days | •••• | |
| Payable Days | •••• | |
| Inventory Days | •••• | |
| Revenue Growth | •••• | |
| Net Profit Growth | •••• | |
Paid data: the figures shown as dots, and every line for FY 2020-21 to FY 2023-24, are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Mediflorence Medicaments are in the company report.
: available in the company report
Board of Directors of Mediflorence Medicaments Limited
Mediflorence Medicaments has 4 current directors and 3 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Sunil Kumar Sharma | Director | 09 Feb 2012 | 14 Years 8 Months | Current |
| Vibhu Sharma | Director | 15 Mar 2021 | 5 Years 7 Months | Current |
| Nishant Agrawal | Director | 30 Sep 2013 | 13 Years 0 Months | Current |
| Bijender Kumar Jain Also directs: Integra Life Sciences Private Limited | Director | 09 Feb 2012 | 14 Years 8 Months | Current |
Auditor Details
Mediflorence Medicaments Limited is audited by HARISH CHANDRA & ASSOCIATES for the financial year 2021.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| HARISH CHANDRA & ASSOCIATES | Locked | Locked | Locked |
: available in the company report
Ownership and Shareholding
: available in the company report
Charges & Borrowings
| Date | Lender | Amount | Status |
|---|---|---|---|
| 08 Nov 2017 | Others | ₹20 Lakh | Open |
Total charge records: 1 View all charges
Employees and EPFO Compliance
Employment history and EPFO contributions of people linked to Mediflorence Medicaments.
: available in the company report
Recent Activity
Mediflorence Medicaments Limited has 7 board changes on record since 2012: 4 appointments and 3 cessations. The latest: Vibhu Sharma ceased to be Additional Director on 15 Nov 2021.
Credit Ratings, Litigation & Regulatory Alerts
: available in the company report
MSME Payment Delays
: available in the company report
Subsidiaries & Group Companies
: available in the company report
GST Compliance
Mediflorence Medicaments has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 09AAICM4762C1ZF | Uttar Pradesh | Active | 01 Jul 2017 |
: available in the company report
MCA Filings & Documents
: available in the company report
Frequently Asked Questions
Mediflorence Medicaments is an active public limited company based in New Delhi, Delhi, India. The company works in pharmaceutical retailers and distributors, within the pharma industry. It was incorporated on 09 February 2012 (14+ years old) and is registered under CIN U24100DL2012PLC231292.
Mediflorence Medicaments has 4 current directors:
- Sunil Kumar Sharma - Director
- Vibhu Sharma - Director
- Nishant Agrawal - Director
- Bijender Kumar Jain - Director
The latest financial statements of Mediflorence Medicaments on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Mediflorence Medicaments is 09AAICM4762C1ZF, registered in Uttar Pradesh.
The CIN (Corporate Identification Number) of Mediflorence Medicaments is U24100DL2012PLC231292. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Mediflorence Medicaments was incorporated on 09 February 2012, making it 14+ years old. It is registered with the Registrar of Companies, Delhi.
Vibhu Sharma ceased to be Additional Director on 15 Nov 2021. Shivali Sharma ceased to be Director on 15 Mar 2021. Vibhu Sharma was appointed as Director on 15 Mar 2021. Mediflorence Medicaments has 7 board changes on record in total.
Yes, Mediflorence Medicaments is registered as a micro enterprise under Udyam registration (number: UDYAM-UP-56-0035076).
Mediflorence Medicaments can be reached through the website mediflorence.com. Its registered office is in New Delhi, Delhi, India.
The registered office of Mediflorence Medicaments is at B – 86 R Block Dilshad Garden, New Delhi, Delhi, India – 110095.